<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290390</url>
  </required_header>
  <id_info>
    <org_study_id>ANNOV3454-2 PMR</org_study_id>
    <nct_id>NCT04290390</nct_id>
  </id_info>
  <brief_title>Annovera™ Drug-Drug Interaction Study</brief_title>
  <official_title>A Drug-Drug Interaction Study to Evaluate the Effects of Strong CYP3A Induction and Inhibition on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol From the Annovera™ Contraceptive Vaginal System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TherapeuticsMD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TherapeuticsMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Drug-Drug Interaction (DDI) study to evaluate the effects of itraconazole and rifampin on&#xD;
      the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol from the Annovera&#xD;
      Contraceptive Vaginal System (CVS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Actual">January 6, 2021</completion_date>
  <primary_completion_date type="Actual">January 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two cohort, open label, randomized, two period (Cycle 1 and Cycle 2) crossover study. Subjects may only participate in one randomized sequence of one cohort. Subjects will be assigned to either Cohort 1 (itraconazole) or Cohort 2 (rifampin). Once assigned, a subject will then be randomized to a Sequence Group within the cohort. There will be at least a 4-week washout between Treatment Cycle 1 and Cycle 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-curve (AUC) of rifampin and itraconzaole on Annovera (segesterone acetate and ethinyl estradiol)</measure>
    <time_frame>Day 1 for itraconazole cohort, Day 11 for rifampin cohort</time_frame>
    <description>AUC for 24 hours for segesterone acetate and ethinyl estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of rifampin and itraconzaole on Annovera (segesterone acetate and ethinyl estradiol)</measure>
    <time_frame>Day 1 for itraconazole cohort, Day 11 for rifampin cohort</time_frame>
    <description>Cmax for segesterone acetate and ethinyl estradiol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of Participants with Adverse Events</measure>
    <time_frame>Screening through 14 days following Annovera removal</time_frame>
    <description>Serious adverse events (SAEs) and adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Vital signs - systolic and diastolic blood pressure</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>Measurements of systolic and diastolic blood pressure will be compared from Screening to end of treatment/end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Vital signs - pulse</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>Measurements of pulse will be compared from Screening to end of treatment/end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability -Discontinuation rates</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>Participant rates of discontinuation due to AEs will provide information regarding tolerability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Women</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Annovera (alone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Annovera taken alone (without itraconazole or rifampin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Annovera with itraconazole use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Annovera with rifampin use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Segesterone Acetate and Ethinyl Estradiol</intervention_name>
    <description>Contraceptive Vaginal System</description>
    <arm_group_label>Annovera (alone)</arm_group_label>
    <arm_group_label>Annovera with itraconazole use</arm_group_label>
    <arm_group_label>Annovera with rifampin use</arm_group_label>
    <other_name>Annovera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>CYP3A inducer</description>
    <arm_group_label>Annovera with rifampin use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>CYP3A inhibitor</description>
    <arm_group_label>Annovera with itraconazole use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        All of the following criteria must be met for the participants to be eligible for the&#xD;
        study:&#xD;
&#xD;
          -  a. Healthy women, non-smoker (no use of tobacco or nicotine products within 3 months&#xD;
             prior to screening) sterile or at risk of becoming pregnant, inclusive of ages 18 to&#xD;
             35* years at the enrollment visit.&#xD;
&#xD;
          -  b. Body Mass Index (BMI) &gt; 18.5 and ≤ 29.0 kg/m2 and body weight ≥ 45.0 kg.&#xD;
&#xD;
          -  c. Intact uterus and both ovaries.&#xD;
&#xD;
          -  d. Prior history of regular menstrual cycles that usually occur every 28 ± 7 days when&#xD;
             not using hormonal contraception; if postpartum or post-abortal, history of regular&#xD;
             menstrual cycles of 21 to 35 days in length and resumption of at least one cycle with&#xD;
             a cycle length consistent with her past cycles.&#xD;
&#xD;
          -  e. In the opinion of the Investigator, able to comply with the protocol, eg, live&#xD;
             within the study site catchment area or within a reasonable distance from the study&#xD;
             site.&#xD;
&#xD;
          -  f. If not sterile and sexually active with a non-sterile male partner, willing to use&#xD;
             one of the following acceptable contraceptive methods throughout the study:&#xD;
&#xD;
          -  intra-uterine contraceptive device without hormone release system placed at least 28&#xD;
             days prior to the start of the first treatment cycle;&#xD;
&#xD;
          -  male condom with intravaginally applied spermicide starting at least 21 days prior to&#xD;
             the start of the first treatment cycle;&#xD;
&#xD;
          -  g. If not sterile and sexually active with a sterile male partner, the partner is at&#xD;
             least 6 months post-vasectomy.&#xD;
&#xD;
          -  h. Willing to abstain from Tylenol/acetaminophen use and from consuming grapefruit or&#xD;
             grapefruit juice from 7 days pre-dose until after the last PK blood sample collection&#xD;
             of each period.&#xD;
&#xD;
          -  i. Willing to abstain from alcohol from 24 hours pre-dose until after the last PK&#xD;
             blood sample collection of each period.&#xD;
&#xD;
          -  j. Signed informed consent prior to entry into the trial.&#xD;
&#xD;
        (*Upper age limit based on normal ovarian changes (ovarian reserve) prevalent in women with&#xD;
        advancing age (&gt; 35 years of age) that may alter patterns of follicle development and/or&#xD;
        confound interpretations of data regarding patterns of follicle development)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Contraindications for enrollment will be the same as those for use of CHCs and additional&#xD;
        criteria important to the objectives of this study and include:&#xD;
&#xD;
          -  a. Known hypersensitivity to estrogens or progestins.&#xD;
&#xD;
          -  b. Pregnant, trying to become pregnant, or breastfeeding.&#xD;
&#xD;
          -  c. Known hypersensitivity to silicone rubber.&#xD;
&#xD;
          -  d. Undiagnosed abnormal vaginal bleeding.&#xD;
&#xD;
          -  e. Undiagnosed vaginal discharge, vaginal lesions or abnormalities. Participants&#xD;
             diagnosed at screening with a chlamydia or gonococcus infection may be included in the&#xD;
             trial following treatment; partner treatment is also recommended. Investigators should&#xD;
             make a determination if participants are at high risk for reinfection, eg, multiple&#xD;
             sex partners, untreated partner, and whether such participants can be included.&#xD;
&#xD;
          -  f. History of pelvic inflammatory disease since the participant's last pregnancy.&#xD;
&#xD;
          -  g. History of toxic shock syndrome.&#xD;
&#xD;
          -  h. In accordance with the Bethesda system of classification: Women with a current&#xD;
             (within the last 20 months) abnormal Papanicolaou smear (Pap smear) suggestive of&#xD;
             high-grade pre-cancerous lesion(s), including high grade squamous intraepithelial&#xD;
             lesion.&#xD;
&#xD;
          -  i. Cystoceles or rectoceles or other anatomical abnormality that would preclude use of&#xD;
             a vaginal ring.&#xD;
&#xD;
          -  j. Women planning to undergo major surgery during the trial.&#xD;
&#xD;
          -  k. Current or past thrombophlebitis or thromboembolic disorders.&#xD;
&#xD;
          -  l. History of venous thrombosis or embolism in a first-degree relative, &lt; 55 years of&#xD;
             age suggesting a familial defect in the blood coagulation system, which in the opinion&#xD;
             of the Principal Investigator (PI), suggests that use of a hormonal contraceptive&#xD;
             could pose a significant risk.&#xD;
&#xD;
          -  m. Cerebrovascular or cardiovascular disease.&#xD;
&#xD;
          -  n. History of retinal vascular lesions, unexplained partial or complete loss of&#xD;
             vision.&#xD;
&#xD;
          -  o. Known or suspected carcinoma of the breast.&#xD;
&#xD;
          -  p. Carcinoma of the endometrium or other known or suspected estrogen-dependent&#xD;
             neoplasia.&#xD;
&#xD;
          -  q. Past history of any other carcinoma unless in remission for more than five years.&#xD;
&#xD;
          -  r. Current or history of medically diagnosed severe depression, which, in the opinion&#xD;
             of the Investigator, could be exacerbated by the use of a hormonal contraceptive.&#xD;
&#xD;
          -  s. Has a Type D personality type as assessed by the DS14 test (Standard Assessment of&#xD;
             Negative Affectivity, Social Inhibition and Type D Personality).&#xD;
&#xD;
          -  t. Headaches with focal neurological symptoms.&#xD;
&#xD;
          -  u. Severe constipation in the opinion of the Investigator.&#xD;
&#xD;
          -  v. History of cholestatic jaundice of pregnancy or jaundice with prior steroid use.&#xD;
&#xD;
          -  w. Benign or malignant liver tumors; active liver disease.&#xD;
&#xD;
          -  x. Diastolic blood pressure (BP) &gt; 85 mm Hg and/or systolic BP &gt; 135 mm Hg after 5 to&#xD;
             10 minutes rest (at Screening).&#xD;
&#xD;
          -  y. Known or suspected alcoholism or drug abuse within their lifetime, or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine, crack, opioid derivatives including heroin, and&#xD;
             amphetamine derivatives) within 1 year prior to screening.&#xD;
&#xD;
          -  z. Elevated serum fasting clinical chemistry values or complete blood count (CBC)&#xD;
             values designated clinically significant by the Investigator and/or medically&#xD;
             qualified Sub-Investigator.&#xD;
&#xD;
          -  aa. Screening hemoglobin levels less than 115 g/L or hematocrit less than 0.32 L/L.&#xD;
&#xD;
          -  bb. Participation in another clinical trial involving the administration of an&#xD;
             investigational drug or marketed drug or device within the last 30 days prior to the&#xD;
             first dosing, administration of a biological product in the context of a clinical&#xD;
             research study within 90 days prior to the first dosing, or concomitant participation&#xD;
             in an investigational study involving no drug or device administration.&#xD;
&#xD;
          -  cc. Use of liver enzyme inducers on a regular basis and sex steroid hormone treatments&#xD;
             (see Section 8.3 for list of exclusionary medications).&#xD;
&#xD;
          -  dd. Use of monthly injectable contraceptives, unless suspended 2 months before&#xD;
             initiation of the treatment. Use of Depo-Provera® [depot medroxyprogesterone acetate]&#xD;
             unless suspended 9 months before treatment.&#xD;
&#xD;
          -  ee. Current use of implanted hormonal contraceptives, including Mirena® [progestin&#xD;
             containing intrauterine system], Jadelle®, Norplant®, Implanon® or Nexplanon (if now&#xD;
             available in the USA).**&#xD;
&#xD;
          -  ff. Known HIV, Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  gg. History of frequent vaginal infections in the opinion of the Investigator.&#xD;
&#xD;
          -  hh. Known hypersensitivity or prior adverse reaction to itraconazole, or to any of the&#xD;
             other azoles or to rifampin, or to any of the rifamycins.&#xD;
&#xD;
        (*Women using non-hormonal intrauterine devices are permitted to enroll in the study.)&#xD;
        (**Participants using any of the implanted hormonal methods who request removal for reasons&#xD;
        unrelated to the purpose of enrollment in this study may be considered for participation.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Mirkin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>TherapeuticsMD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syneos Health</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1P OA2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampin</keyword>
  <keyword>itraconazole</keyword>
  <keyword>CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

